Lu AE58054

Lu AE58054

Lu AE58054 is a potent and selective 5-HT6 receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer's disease and schizophrenia.[1][2] As of February 2010 it is in phase II clinical trials.[2]

References

External links

  • Lundbeck expands its pipeline - initiating phase II clinical trials with a new compound for the treatment of schizophrenia
  • Lundbeck initiates clinical phase II trials with Lu AE58054 as augmentation treatment in Alzheimer's disease